Information Provided By: 
Fly News Breaks for February 7, 2017
MYGN
Feb 7, 2017 | 06:12 EDT
Piper Jaffray analyst William Quirk says that despite around 20 payers updating their coverage policies for the new year, not one payer issued a favorable coverage decision for Myriad Genetics' Prolaris, Vectra DA or GeneSight. While the company's FY17 guidance does not assume incremental reimbursement coverage for these tests, private coverage is necessary for revenue upside, Quirk tells investors in a research note. He keeps a Neutral rating on Myriad shares with a $21 price target.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
